Which heart valve prosthesis for patients aged between 60 and 70 years?

G Hanania

The advantages and disadvantages of the two types of heart valves—mechanical and bioprostheses—can pose a dilemma when it comes to choosing the most appropriate treatment for patients aged between 60 and 70 years.

Prosthetic valve replacement has transformed the prognosis of major and poorly tolerated valvulopathies. The respective advantages and disadvantages of the two types of valves available are well known: mechanical prostheses (MP) theoretically have an indeterminate life span but carry the risk of thromboembolic events that require anticoagulant therapy, which itself is responsible for haemorrhages; bioprostheses (BP), free of anticoagulant treatment and thus haemorrhagic risk, bear a theoretically lower thromboembolic risk (but in fact equal to that of an anticoagulated MP) and have a limited life span that requires reintervention at a subsequent date influenced by the patient's age at implantation, the valve replaced, and the BP type used.

These respective risks affect the long term outcome of the prosthesis bearer and differ by their time of occurrence. Thromboembolic and haemorrhagic events can occur at any time during the postoperative period, whereas BP deterioration, highly unusual during the first few years after implantation, can occur as early as the 10th year or even earlier, especially in patients younger at the time of surgery and those with mitral valvulopathy, and is seen in almost all patients by 20 years.

The indication for a BP must take into account the contraindications for anticoagulants, the patient's informed consent, and his/her life expectancy at the time of the intervention. This latter essential factor explains the preference for an MP before 60 years and a BP after 70 years. However, a consensus has not yet been reached for the seventh decade, between 60 and 70 years, even though the American College of Cardiology/American Heart Association recommendations set the respective age limits for aortic and mitral bioprostheses at 65 and 70 years.

LONG TERM OUTCOMES

Good long term outcomes have been obtained with these different replacement valves, but comparisons between MP and BP are less common. The Edinburgh heart valve trial randomized 533 patients, 261 with mitral and 211 with aortic valvulopathies, to receive either a Bjork MP or a Hancock or Carpentier–Edwards porcine BP. After 20 years of follow up, no difference between the survival rates of the two groups was observed. The reoperation rate was higher for the BP group, while more patients with MP haemorrhaged.

The Veterans Affairs (VA) trial randomised 575 men to receive either a Bjork or Hancock prosthesis with 394 aortic and 181 mitral replacements. With 15 years of follow up, survival was better for patients receiving an aortic MP than a BP and was comparable for mitral valve replacements. Haemorrhages were more common with mechanical valves, but no significant difference was noted for thromboembolic and infective complications. Notably, BP deteriorated even more frequently when the subject was younger at the time of surgery: 26% before 65 years and 9% thereafter for aortic replacements, and 44% for mitral valves in patients under 65 years.

A retrospective French study on a highly homogeneous cohort, defined by their year of intervention (1985), length of follow up, and age at the time of surgery between 60 and 70 years (all born between 1915 and 1925), gave results similar to those reported by the VA. Among the 574 patients enrolled, 497 had monovalvar replacements: 313 aortic (160 MP and 153 BP) and 184 mitral (99 MP and 85 BP).

Overall survival was better for the patients receiving MP (46%) than porcine valves (32%) to replace defective aortic valves, and rates were equivalent in the mitral position (34% and 33%, respectively).

The BP deterioration rate at 15 years was 48% for mitral valves versus 20% for aortic valves, representing 28.2% and 8.5%, respectively, of the initially operated population. The percentages of aortic and mitral BP deterioration varied as a function of the patient's age at the time of implantation: 13.5% and 32.6% before 65 years, 3.8% and 22.2% thereafter, respectively. Postoperative mortality for reoperated patients was 9%.

The rates of thromboembolic events were comparable for mitral MP and BP (19%) versus only 5% for aortic BP and 8% for MP. Finally, haemorrhages clearly occurred more frequently in MP bearers—15% of aortic and 12% of mitral valves—as opposed to 6% for mitral BP more commonly associated with anticoagulant treatment, and 2% for aortic BP.

ELDERLY PATIENTS

BP tend to be preferred for elderly patients, but some authors have provided favourable long term outcomes influenced by the patient's age at implantation, the valve replaced, and the BP type used. The indication for a BP must take into account the contraindications for anticoagulants, the patient's informed consent, and his/her life expectancy at the time of the intervention. This latter essential factor explains the preference for an MP before 60 years and a BP after 70 years. However, a consensus has not yet been reached for the seventh decade, between 60 and 70 years, even though the American College of Cardiology/American Heart Association recommendations set the respective age limits for aortic and mitral bioprostheses at 65 and 70 years.

**Abbreviations:** BP, bioprosthesis; INR, international normalised ratio; MP, mechanical prosthesis; VA, Veterans Affairs
results for bileaflet valves. The weak thrombogenicity of the latter, the possibility of moderate anticoagulation for aortic prostheses with an international normalised ratio (INR) of 2–3, the foreseeable widespread use of self testing to control anticoagulation, and the frequent indications of oral anticoagulant for atrial fibrillation associated with mitral valve replacements are all arguments supporting the extension of MP use to elderly subjects.

On the other hand, valid arguments favour retaining BP as the reference aortic prosthesis for aged individuals: no need for anticoagulant treatment, which is always difficult to pursue at an age when extracardiac disease(s) is ever more common, and low frequency of deterioration before the 15th year post-surgery. Henceforth, the choice will be guided by life expectancy at the time of the intervention and the surgical risk of reoperation for BP deterioration in the elderly subject. In France, life expectancy predictions for women and men, respectively, are 25.7 and 19.5 years at 60 years of age, 20.4 and 16 years at 65, and 16.3 and 12.7 years at 70.

Based on the reported deterioration rates of mitral BP, they do not appear to be good replacement valves in this position before 70 years of age. The seventh decade thus remains the domain of the MP for mitral valve replacement.

For aortic valvulopathies, the choice is more subtle. For valves replaced before 65 years, the reinvention rate around 80 years remains high, affecting close to 10% of patients. Furthermore, this percentage will continue to rise because life expectancy in developed countries, where it was expected to stabilise, has continued to increase. The elderly subject’s risk of reoperation has been estimated to be 6–11%.

• Morbidity attributable to these reinterventions is much higher, affecting 34% of the reoperated population. After 65 years, the possible need for reinvention because of deterioration is lower and the aortic BP can be preferred over the MP for certain patients.

SUMMARY

The seventh decade is, in terms of valve replacement, a transitional period during which the choice between MP and BP must take into consideration multiple parameters that determine the long term postoperative outcome.

• The thromboembolic risk is theoretically equivalent for both valve substitutes (under oral anticoagulation for MP and without for BP); however, an added risk exists for the former should extracardiac surgery, frequent at these ages, be necessary.

• Anticoagulant treatment for MP and/or atrial fibrillation bears an inherent haemorrhagic risk and, when prolonged beyond 80 years, increases the frequency and severity of such events, even though the use of moderate anticoagulation is authorised for currently available aortic MP and the imminent development of self testing promises to lower this risk.

• The predictable time at which a primary BP will fail is even longer for the older subject and when the aortic position is involved.

• Life expectancy of the subject should be less than the foreseeable deterioration of the replacement valve.

• The risk of reinvention for prosthesis deterioration at 80 years and older must be taken into consideration.

• The patient’s own characteristics—extracardiac disease(s) shortening life expectancy or contraindicating anticoagulants, impossibility of achieving optimal treatment monitoring and, on the other hand, indication of anticoagulant treatment for atrial fibrillation—must be entered into the equation.

• Finally, the patient has to make his or her own decision, after being fully informed of the two therapeutic options.

At the end of this analysis, and in light of the results reported in the literature, the logical choice for mitral valve replacement before 70 years is an MP. For an aortic valve and before 65 years, today’s life expectancy is such that an MP remains the best solution to avoid reinvention, which is always more risk laden than primary surgery in an octogenarian. Between 65 and 70 years, the choice is less restricted. The preference should continue, especially in women endowed with a longer mean life span, to favour MP with the possibility of moderate anticoagulant treatment (INR of 2–3.5) without excessive morbidity over a prolonged postoperative period, including essentially the eighth decade.

REFERENCES


